Bellerophon Therapeutics Inc (NASDAQ:BLPH) was the recipient of a large decline in short interest in the month of March. As of March 29th, there was short interest totalling 626,923 shares, a decline of 27.0% from the March 15th total of 858,324 shares. Based on an average daily volume of 215,071 shares, the short-interest ratio is presently 2.9 days. Currently, 1.2% of the company’s shares are short sold.

In other news, Director Naseem Amin purchased 571,429 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The stock was purchased at an average cost of $0.70 per share, with a total value of $400,000.30. Following the purchase, the director now owns 1,818,867 shares in the company, valued at $1,273,206.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 53.10% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in shares of Bellerophon Therapeutics by 4.7% during the 3rd quarter. Renaissance Technologies LLC now owns 1,213,276 shares of the biotechnology company’s stock worth $1,310,000 after purchasing an additional 54,076 shares during the period. Vanguard Group Inc boosted its position in Bellerophon Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after buying an additional 25,300 shares during the period. Virtu Financial LLC boosted its position in Bellerophon Therapeutics by 60.2% in the 4th quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 13,799 shares during the period. Finally, Geode Capital Management LLC boosted its position in Bellerophon Therapeutics by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 27,027 shares during the period. 47.63% of the stock is owned by hedge funds and other institutional investors.

BLPH stock opened at $0.64 on Tuesday. Bellerophon Therapeutics has a 12 month low of $0.47 and a 12 month high of $3.30. The stock has a market cap of $44.96 million, a P/E ratio of -1.88 and a beta of -0.01.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.10. As a group, analysts predict that Bellerophon Therapeutics will post -0.52 earnings per share for the current year.

A number of equities analysts recently commented on the stock. ValuEngine cut shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Tuesday, January 1st. Maxim Group set a $3.00 price target on shares of Bellerophon Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2019/04/16/bellerophon-therapeutics-inc-blph-sees-large-decline-in-short-interest.html.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Read More: How to calculate compound interest

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.